Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

Summary

The goal of this study is to test neoadjuvant therapy with the dual inhibition of Programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) immune checkpoint pathways in a cohort of treatment-naïve, resectable stage II to IV cutaneous squamous cell carcinoma on the pathological response rate (pCR) and recurrence-free survival.

Timeline

Start

2024-06-21

Primary completion

2026-09

Completion

2036-07

Drugs

Indications